A randomized phase II trial (NCT02519322) testing the clinical efficacy of the Nivolumab as monotherapy in combination with the anti-CTLA-4 antibody Ipilimumab in patients with high-risk resectable melanoma was terminated early because of the high incidence of trAEs. This evidence concerns the gene CTLA4 and melanoma.